Scancell Holdings plc (AIM:SCLP)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX 85.00
-1.40 (-1.62%)
Nov 4, 2026, 4:35 PM GMT
Scancell Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
103.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2026 | - | - | - |
| Apr 30, 2025 | 4.71M | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | 5.27M | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioventix | 12.97M |
| IXICO | 7.28M |
| PureTech Health | 4.80M |
| Ondine Biomedical | 1.53M |
| Faron Pharmaceuticals Oy | 1.14M |
| Arecor Therapeutics | 890.00K |
| 4basebio | 781.00K |
| Avacta Group | 113.00K |
Scancell Holdings News
- 26 days ago - Scancell Holdings Annual report: H2 2026 - Filings
- 7 weeks ago - Scancell Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 months ago - Scancell Holdings Slides: Corporate presentation - Filings
- 6 months ago - Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study - GlobeNewsWire
- 9 months ago - Scancell Holdings Earnings Call Transcript: H1 2026 - Transcripts
- 9 months ago - Scancell Holdings Quarterly report: H1 2026 - Filings
- 9 months ago - Scancell Holdings Slides: H1 2026 - Filings
- 9 months ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire